HomeTrialNCT05648591
🔬NCT05648591Phase 4RECRUITING

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Study Summary

To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment100 participants
Primary Completion
Lead SponsorVanda Pharmaceuticals
Data Retrieved2026-04-11 04:31:05.188485+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.